Oxurion NV
Biopharmaceutical company providing Contract Research Organization (CRO) services to life sciences.
OXUR | BR
Overview
Corporate Details
- ISIN(s):
- BE0974487192
- LEI:
- 549300VWY8KVDFKLDM59
- Country:
- Belgium
- Address:
- Gaston Geenslaan 1, 3001 Heverlee
- Website:
- https://oxurion.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Oxurion NV is a biopharmaceutical company undergoing a strategic transition. Historically, the company focused on pioneering treatments for retinal diseases, such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD), using innovative approaches including a CRISPR-based target discovery platform. Following a recent strategic shift, Oxurion has ended its internal R&D program in Geographic Atrophy to refocus its business on providing Contract Research Organization (CRO) services to the life sciences sector.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Oxurion NV and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-08 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250903.pdf
|
English | 371.9 KB | |
| 2025-09-08 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250903.pdf
|
Dutch | 396.3 KB | |
| 2025-09-01 18:00 |
Capital/Financing Update
OXUR-Contrat-atlas-crypto-EN-20250901.pdf
|
English | 190.2 KB | |
| 2025-09-01 18:00 |
Capital/Financing Update
OXUR-Contrat-atlas-crypto-FR-20250901.pdf
|
French | 125.2 KB | |
| 2025-09-01 18:00 |
Capital/Financing Update
OXUR-Contrat-atlas-crypto-NL-20250901-1.pdf
|
Dutch | 214.2 KB | |
| 2025-09-01 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250901.pdf
|
English | 1.2 MB | |
| 2025-09-01 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250901.pdf
|
English | 1.3 MB | |
| 2025-08-07 18:00 |
Legal Proceedings Report
OXUR-New-Development-Strategy-EN-20250806.pdf
|
English | 195.7 KB | |
| 2025-08-07 18:00 |
Regulatory News Service
FR_OXURION_PR_New-Development-Strategy_SD_20250806.pdf
|
French | 133.2 KB | |
| 2025-08-07 18:00 |
Earnings Release
OXUR-New-Development-Strategy-NL-20250806.pdf
|
Dutch | 213.8 KB | |
| 2025-08-07 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250807.pdf
|
English | 479.6 KB | |
| 2025-08-07 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250807.pdf
|
English | 506.8 KB | |
| 2025-08-06 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250806.pdf
|
English | 509.9 KB | |
| 2025-08-06 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250806.pdf
|
English | 539.6 KB | |
| 2025-08-04 18:00 |
Capital/Financing Update
UK_OXURION_PR_PR_30M-Funding.pdf
|
English | 194.3 KB |
Automate Your Workflow. Get a real-time feed of all Oxurion NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Oxurion NV via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-03-07 | Bareldam SA | Close relation | Buy | 1,180,555 | 1,700,000.00 EUR |
| 2021-09-30 | Lavinia D. Clay 2009 Revocable Trust | Close relation | Other | 2,766,337 | 5,601,002.52 EUR |
